alexa Abstract | Monitoring Enoxaparin with Antifactor Xa Levels in Severe Renal Impairment
ISSN: 2376-0419

Journal of Pharmaceutical Care & Health Systems
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article Open Access


Backgrounds: While several large clinical trials have proven the efficacy and safety of treatment with enoxaparin, most of these studies excluded patients with severe renal impairment and to date no large randomized studies have been conducted that assess the safety and efficacy of the drug in this subset of patients. Objectives: To characterize antifactor Xa peak levels as therapeutic, subtherapeutic, or supratherapeutic, in nondialysis patients with severe renal impairment who are receiving renally adjusted therapeutic doses of enoxaparin and to assess the incidence of bleeding complications in these patients. Methods: Retrospective cohort study in a community hospital evaluating seventy-five severe renal impairment patients (creatinine clearance [CrCl] < 30 mL/min) who received at least three renally adjusted therapeutic doses of enoxaparin and had steady-state antifactor Xa peak levels collected between April 2009 and April 2015. Institutional review board approval was obtained to collect data from patients' medical records. The primary outcome was the proportion of patients whose steady-state antifactor Xa peak levels were in the therapeutic, subtherapeutic, or supratherapeutic ranges. The secondary outcome was the incidence of major bleeding. Results: The final analysis showed that 63% of patients (n=47) had therapeutic levels, 22% (n=17) had subtherapeutic levels, and 15% (n=11) had supratherapeutic levels. No major bleeding incidents identified in the study. Conclusion: Based on the results of this study, monitoring antifactor Xa levels is warranted to ensure the safety and efficacy of renally adjusted doses of therapeutic enoxaparin in non-dialysis patients with severe renal impairment.

To read the full article Peer-reviewed Article PDF image | Peer-reviewed Full Article image

Author(s): Jose A Vega, Young R Lee, Danni McMahan and Hanh-Nhi Q Duong


Lovenox, Low molecular weight heparin, Enoxaparin, Renal impairment, Antifactor Xa level monitoring, Therapeutic monitoring, Pharmacy Education, Pharmaceutical Care Practice

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version